Shop
Description
Ranolazine 500 mg Extended-Release Tablets (brand name RANCV) are used to treat stable angina pectoris in adults who are inadequately controlled or intolerant to first-line antianginal therapies.
**Drug Class or Type:**
– Anti-anginal agent.
**General Mechanism of Action:**
– Ranolazine works by inhibiting the entry of sodium and potassium into heart muscle cells, thereby managing calcium influx, causing vasodilation, and reducing ventricular tension and myocardial oxygen demand. This mechanism helps relieve angina symptoms. ([netmeds.com](https://www.netmeds.com/prescriptions/rancv-500-tablet-10s?utm_source=openai))
**Common Forms:**
– Extended-release tablets.
**Dosage Instructions:**
– The recommended initial dose is 375 mg twice daily. After 2–4 weeks, the dose should be titrated to 500 mg twice daily and, according to the patient’s response, further titrated to a recommended maximum dose of 750 mg twice daily. ([efda.gov.et](https://www.efda.gov.et/wp-content/uploads/2023/08/Ranolazine-500-mg-Extended-release-tablets-_RANCV-500_MSN-Laboratories-Private-Limited.pdf?utm_source=openai))
Ranolazine 500 mg Extended-Release Tablets are intended for the management of stable angina pectoris and should be used under medical supervision.
Reviews
There are no reviews yet.